Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14740338.2021.1970744 http://scihub22266oqcxt.onion/10.1080/14740338.2021.1970744 34424130!8425441!34424130     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Drug+Saf 2021 ; 20 (11): 1309-1315 Nephropedia Template TP {{tp|p=34424130|t=2021. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism |pdf=|usr=}}{{34424130}} gab.com Text The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism JO: Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34424130 #FOAvip INTRODUCTION: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. AREAS COVERED: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. EXPERT OPINION: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature. Twit Text FOAVip The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism ????Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34424130 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34424130 #FOAvip English Wikipedia <ref>{{Cite pmid|34424130}}</ref> The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism #MMPMID34424130 Banerjee Y; Pantea Stoian A; Silva-Nunes J; Sonmez A; Rizvi AA; Janez A; Rizzo M Expert Opin Drug Saf 2021[Nov]; 20 (11): 1309-1315 PMID34424130show ga INTRODUCTION: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. AREAS COVERED: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. EXPERT OPINION: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |COVID-19/epidemiology/metabolism/virology[MESH] |Diabetes Mellitus, Type 2/*drug therapy/epidemiology/metabolism[MESH] |Glucagon-Like Peptide-1 Receptor/*agonists/metabolism[MESH] |Humans[MESH] |Hypoglycemic Agents/adverse effects/*therapeutic use[MESH] |Incretins/adverse effects/*therapeutic use[MESH] |Signal Transduction[MESH]The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypoth(epmc).pdf DeepDyve Pubget Overpricing